Precision Optics Announces $1.3 Million Product Expansion Development Agreement for Next Generation Urological Endoscopy Program

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the receipt of an initial product development order for a next-generation urological endoscopy program totaling approximately $1.3 million from an established medical device company. The development program will expand Precision Optics’ value-added solutions role from a components supplier to the developer of the entire endoscope imaging system. This opportunity leverages the Company’s unique combination of expertise in micro-optics, medical systems, digital imaging, and system integration.

The development of the next-generation urological endoscope will be undertaken by the combined Precision Optics and Lighthouse Imaging engineering teams, further evidencing the team’s unique value proposition and capabilities. The initial development agreement is expected to be completed over the coming 12 months, with opportunities for future development and commercial production contracts upon successful completion and approval.

“This new development agreement marks a significant opportunity for Precision Optics to continue our move up the value creation chain for our customers by leveraging our enhanced engineering expertise across all aspects of endoscope development,” commented Dr. Joe Forkey, CEO of Precision Optics. “Our engineering product development pipeline remains robust as customers are increasingly understanding the fully integrated optics and electronics capabilities we provide to help bring next generation medical imaging products to the market. We look forward to the continued advancement of this new program in the coming years.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.